{
  "docId": "019de073-7953-75ff-b7a7-421adee0c76c",
  "docSlug": "f2ba5faea717d1fc1a89b119873b0327",
  "documentTitle": "Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides",
  "authorId": "anebulo-pharmaceuticals",
  "authorName": "Anebulo Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 53,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a flow diagram to illustrate the randomized, double-blind, placebo-controlled study structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7953-75ff-b7a7-421adee0c76c/31",
  "deckHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c",
  "deckJsonHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c.json",
  "deckAnchorHref": "/decks/019de073-7953-75ff-b7a7-421adee0c76c#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.09,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "callout",
      "text": "Primary Objective: To investigate the ability of ANEB-001 to inhibit the psychotropic effects of Δ9-Tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f463c09a-e041-4378-b557-a520427d2408",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.65,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Study flow diagram showing 14 volunteers splitting into two groups (THC+Placebo vs THC+ANEB-001) followed by a 7-14 day follow-up.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4bb2f156-243c-40a9-83f0-328dcb08a214",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.71,
        "y": 0.3
      },
      "kind": "list",
      "text": "Endpoints: Primary: inhibition of central nervous system effects of THC (Feeling High, Alertness, Body sway, Heart rate). Secondary: additional efficacy metrics, safety/tolerability, PK, PK/PD correlations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "54286672-c0e8-48f1-8010-63ff97e59bc8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Part B Cohort 1 – Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b61eddcf-d7c3-4683-9e83-e6a9be2224eb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "e97c8126-6085-4a52-accd-36776f339947",
      "evidence": "The slide outlines a randomized, double-blind, placebo-controlled study structure with cohorts, dosing, and endpoints.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 48,
      "from": 13,
      "beatId": "684e64de-8d19-434b-83aa-4bfe1e4eb804",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 13-48 present ANEB-001 as a solution, detailing its pharmacology, clinical trial results, and development plan.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}